Ondansetron Orally Disintegrating Tablets

Product Composition & Available Formats

We supply Ondansetron ODT in the two primary compendial configurations required to support initial introductory pediatric dosing up to high-potency surgical and oncological maintenance regimens.

Ondansetron Orally Disintegrating Tablets USP / BP / IP (4 mg / 8 mg)

Fast-Dissolving Selective Serotonin 5-HT3 Receptor Antagonist Antiemetic

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO services provider, and wholesale supplier of advanced gastroenterology, oncology supportive care, and surgical therapeutics. We manufacture an internationally standardized, high-precision selection of Ondansetron Orally Disintegrating Tablets (ODT) within our state-of-the-art, WHO–GMP certified solid dosage cleanroom facilities.

Serving as a premium, fast-acting clinical asset to halt severe emetic reflexes without requiring water intake, this specialized drug delivery system represents a high-velocity strategic export to oncology treatment networks, surgical hospital groups, national healthcare procurement pipelines, and international digital B2B pharmaceutical marketplaces across the CIS region, Sub-Saharan Africa, LATAM, and South-East Asia.

Product Overview

This formulation operates as a "Peripheral & Central Serotonin Signal Interrupter." It ensures immediate antiemetic stabilization by physically blocking the specific nerve channels that trigger the brain's vomiting center when the gastrointestinal tract faces acute chemotherapeutic, surgical, or cellular stress.

• Mechanism 1 (Selective 5-HT3 Receptor Antagonism): Ondansetron is an exceptionally potent, highly competitive antagonist at Serotonin Type 3 ($\text{5-HT}_{3}$) receptors. It executes this blockade with high specificity, displaying zero cross-reactivity with dopamine, histamine, or muscarinic receptors.

• Mechanism 2 (Peripheral Vagal Veto): Cancer chemotherapeutics, radiation, and surgical manipulation physically trigger enterochromaffin cells in the small intestine mucosa to release massive amounts of serotonin. This serotonin normally binds to vagal afferent nerve $\text{5-HT}_{3}$ receptors, sending severe emetic signals to the brain. Ondansetron physically blocks these peripheral nerve receptors, stopping the signal at the source.

• Mechanism 3 (Central Chemoreceptor Suppression): Concurrently, the molecule targets and blocks central $\text{5-HT}_{3}$ receptors situated inside the Chemoreceptor Trigger Zone (CTZ) in the Area Postrema of the brainstem. This dual peripheral and central action completely neutralizes the vomiting reflex cascade, preventing both acute nausea and active physical retching.

Product Composition & Available Formats

We supply Ondansetron ODT in the two primary compendial configurations required to support initial introductory pediatric dosing up to high-potency surgical and oncological maintenance regimens.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the alimentary tract / Antiemetics / Serotonin Antagonists)

• CAS Number: 99614-02-5 (Ondansetron Base) / 103639-04-9 (Ondansetron Hydrochloride Dihydrate)

• Dosage Form: Orally Disintegrating Tablet (ODT) (Engineered to dissolve completely on the tongue within 10 to 15 seconds without requiring water or swallowing efforts)

• Packaging Configurations: 10 Tablets per Blister Strip packed exclusively in high-barrier Alu-Alu (Cold-Form Foil) with Peel-Off Backing Laminates. ODT matrices are physically delicate and highly hygroscopic; our specialized tropicalized foil packaging isolates every individual tablet from environmental moisture while preventing mechanical breakage during transit, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.

Advanced ODT Matrix Engineering & Quality Attributes